EUCTR2015-001747-37-LT进行中（未招募）不适用
A phase 3, single-dose, multicenter, randomized, double-blind, parallel group study to assess the efficacy and safety of palonosetron 0.25 mg administered as a 30-minute IV infusion compared to palonosetron 0.25 mg administered as a 30-second IV bolus for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving highly emetogenic chemotherapy.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 440
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Signed written informed consent.
- •2. Male or female patient = 18 years of age.
- •3. Histologically or cytologically confirmed solid tumor malignancy.
- •4. Naïve to cytotoxic chemotherapy. Previous biological or hormonal therapy is permitted.
- •5. Scheduled to receive first course of one of the following reference HEC, alone or in combination with other chemotherapeutic agents* on Day 1:
- •- cisplatin administered as a single IV dose of = 70 mg/m2
- •- cyclophosphamide = 1500 mg/m2
- •- carmustine (BCNU) > 250mg/m2
- •- dacarbazine (DTIC)
- •- mechloretamine (nitrogen mustard)
- •The administration of the reference HEC should not extend beyond 4 hours on study Day 1.
- •* on Day 1, additional chemotherapeutic agents have to be administered after the start of the reference HEC administration and their administration must be completed no more than 6 hours after the start of reference HEC infusion. Low, minimally or not emetogenic chemotherapies can be administered at any time from Day 2 onwards.
- •6. ECOG Performance Status of 0, 1, or 2.
- •7. Non-childbearing female patient or female patient of childbearing potential using reliable contraceptive measures and having a negative urine pregnancy test.
- •8. Hematologic and metabolic status adequate for receiving a HEC regimen and fulfillment of the following criteria:
- •a) Total Neutrophils = 1500/mm3 (Standard units: = 1.5 x 10^9/L)
- •b) Platelets = 100,000/mm3 (Standard units: = 100.0 x 10^9/L)
- •c) Bilirubin = 1.5 x Upper Limit of Normal (ULN)
- •d) Liver enzymes:
- •i. Without known liver metastases, Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) = 2.5 x ULN
- •ii. With known liver metastases, AST and ALT = 5.0 x ULN
- •e) Serum Creatinine = 1.5 mg/dL (Standard units: = 132.6 µMOL/L) or Creatinine Clearance = 60 mL/min.
- •9. If a patient has a known hepatic or renal impairment, he/she may be enrolled in this study at the discretion of the Investigator, provided the inclusion criterion #8 items d) and e) are satisfied.
- •10. If a patient has a known history or predisposition to cardiac conduction interval abnormalities, including QTc, he/she may be enrolled in this study at the discretion of the Investigator.
- •11. Able to read, understand, follow the study procedure and complete the patient diary.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 350
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 90
排除标准
- •1. Lactating woman.
- •2. Current use of illicit drugs or current evidence of alcohol abuse.
- •3. Scheduled to receive moderately or highly emetogenic chemotherapies from Day 2 to Day 5.
- •4. Received or is scheduled to receive radiation therapy to the abdomen or the pelvis within 1 week prior to the start of reference HEC administration on Day 1 or between Days 1 to 5.
- •5. Any vomiting, retching, or nausea (grade = 1 as defined by National Cancer Institute) within 24 hours prior to the start of reference HEC administration on Day 1.
- •6. Symptomatic primary or metastatic CNS malignancy.
- •7. Active peptic ulcer disease, gastrointestinal obstruction, increased intracranial pressure, hypercalcemia, an active infection or any illness or medical conditions (other than malignancy) that, in the opinion of the Investigator, may confound the results of the study, represent another potential etiology for emesis and nausea (other than chemotherapy-induced nausea and vomiting [CINV]) or pose unwarranted risks in administering the study drugs to the patient.
- •8. Known hypersensitivity or contraindication to 5-HT3 receptor antagonists (e.g., palonosetron, ondansetron, granisetron, dolasetron, tropisetron, ramosetron) or dexamethasone.
- •9. Known contraindication to the IV administration of 50 mL 5% glucose solution.
- •10. Participation in a previous clinical trial involving palonosetron.
- •11. Any investigational drugs (other than those given in this study) taken within 4 weeks prior to Day 1, and/or is scheduled to receive any investigational drug during the present study.
- •12. Systemic corticosteroid therapy at any dose within 72hours prior to the start of reference HEC administration on Day 1. However, topical and inhaled corticosteroids are permitted.
- •13. Scheduled to receive bone marrow transplantation and/or stem cell rescue therapy.
- •14. Any medication with known or potential antiemetic activity within 24 hours prior to the start of reference HEC administration on Day 1, including:
- •5-HT3 receptor antagonists (e.g., ondansetron, granisetron, dolasetron, tropisetron, ramosetron, palonosetron)
- •NK-1 receptor antagonists (e.g., aprepitant or any other new drug of this class)
- •benzamides (e.g., metoclopramide, alizapride)
- •phenothiazines (e.g., prochlorperazine, promethazine, fluphenazine, perphenazine, thiethylperazine, chlorpromazine)
- •benzodiazepines (except if the subject is receiving such medication for sleep or anxiety and has been on a stable dose for at least seven days prior to Day 1).
- •butyrophenones (e.g., haloperidol, droperidol)
- •anticholinergics (e.g., scopolamine, with the exception of inhaled anticholinergics for respiratory disorders, e.g., ipratropium bromide)
- •antihistamines (e.g., cyclizine, hydroxyzine, diphenhydramine, chlorpheniramine)
- •domperidone
- •mirtazapine
- •olanzapine
- •prescribed cannabinoides (e.g., tetrahydrocannabinol or nabilone)
- •Over The Counter (OTC) antiemetics, OTC cold or OTC allergy medications.
- •15. Concurrent medical condition that would preclude administration of dexamethasone for 4 days such as systemic fungal infection or uncontrolled diabetes.
研究者
相似试验
进行中（未招募）
不适用
A single-dose study to asses the efficacy and safety of palonosetron administered as 30-minute infusion compared to palonosetron administered as a 30-second injection for preventing chemotherapy-induced nausea and vomiting in cancer patients.nausea and vomiting in cancer patients receiving highly emetogenic therapyMedDRA version: 18.0Level: LLTClassification code 10036899Term: Prophylaxis against chemotherapy induced vomitingSystem Organ Class: 100000004865EUCTR2015-001747-37-HUHelsinn Healthcare SA440
进行中（未招募）
不适用
A single-dose study to asses the efficacy and safety of palonosetron administered as 30-minute infusion compared to palonosetron administered as a 30-second injection for preventing chemotherapy-induced nausea and vomiting in cancer patients.nausea and vomiting in cancer patients receiving highly emetogenic therapyMedDRA version: 18.1Level: LLTClassification code 10036899Term: Prophylaxis against chemotherapy induced vomitingSystem Organ Class: 100000004865EUCTR2015-001747-37-GRHelsinn Healthcare SA440
已完成
3 期
A clinical trial to study the effect of Fenticonazole Vaginal Capsule in treatment of vaginal candidiasis (fungal infection of female genitals characterized by itching, redness and white discharge).CTRI/2014/10/005082Glenmark Pharmaceuticals Ltd430
进行中（未招募）
1 期
Immunogenicity and Safety Evaluation of AdimFlu-S (QIS) in Healthy Subjects.EUCTR2016-001557-41-BEAdimmune Corporation2,100
尚未招募
3 期
A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants with Active Systemic Lupus Erythematosus.Systemic Lupus ErythematosusNL-OMON51320Biogen12